FILE - In this photo illustration, the Eli Lilly and Company logo is seen displayed on a smartphone. LOS ANGELES - The U.S.
Food and Drug Administration issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy bamlanivimab to treat mild-to-moderate cases of COVID-19, according to a news release.“Monoclonal antibodies are used to treat many diseases, including some types of cancer.